GH Research is developing GH001, an inhalable mebufotenin therapy targeting treatment-resistant depression. The company reported strong Phase 2b clinical trial results and plans to start a global Phase 3 program in 2026. GH001 is notable for its rapid onset and short psychedelic experience, which may offer advantages over competitors. Despite uncertainties about real-world performance, GH Research is viewed as undervalued due to the large market potential and significant unmet medical needs in depression treatment.
Cardano is experiencing a major governance crisis in 2026 due to tensions between supporters of academic blockchain research and developers demanding quicker commercial results. The debate centers on whether treasury funds should prioritize long-term...
Bitcoin remains steady above $77,000 following a sharp recovery, driven by strong institutional buying and a shift away from altcoins. Despite retail trader fear and Bitcoin ETF outflows, large investors are accumulating BTC, supported by improving M...
Hyperliquid's native token HYPE has overtaken Dogecoin (DOGE) to claim the 9th spot in global cryptocurrency rankings, reaching a market cap of $16.03 billion. This rise follows a 47% weekly gain driven by Hyperliquid's automated DeFi buyback mechani...
C-Lingo, a Hong Kong-based company, introduced a new AI-driven platform on May 23, 2026, to transform Chinese language education in Vietnam. The platform uses a unique "Connected Learning" model combining AI personalization and gamification to enhanc...
XRP is struggling near the $1 mark despite $116.74 million inflows into U.S. spot ETFs, with a potential drop to $1.05 unless a U.S. Senate vote on the CLARITY Act reverses the trend. Bitcoin, despite $1.26 billion in weekly ETF outflows, has held su...
